Healthcare Industry News: PD-L1
News Release - June 8, 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy OfficerSEATTLE, June 8, 2021 -- (Healthcare Sales & Marketing Network) -- Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.
"David comes to Umoja with a wealth of leadership experience in drug development and business strategy," said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma. "His extensive expertise in the biotech and biopharma sectors and proven track record of bringing novel oncology drugs from development all the way through to commercialization will be invaluable as we advance our in vivo cell therapies into the clinic."
Fontana joins Umoja from Bristol Myers Squibb, where he was an executive in the Cell Therapy Franchise and part of the Lymphoma Disease Strategy Team. There, he led the development of CD19 CAR T cell therapy BREYANZI® from clinical evaluation to commercialization. Prior to this role, he led the advancement of late-stage immuno-oncology assets and translational medicine as Vice President of Immuno-Oncology at Pfizer. Fontana has successfully guided multiple drug candidates to significant milestones throughout his career, including ADCETRIS® (CD30 antibody-drug conjugate, Brentuximab vedotin), BAVENCIO® (avelumab, anti PD-L1), and relatlimab, (anti-LAG-3 antibody). Fontana received a Ph.D. in Pharmacology from Wayne State University and holds a PMP certification from the Project Management Institute.
"Umoja's integrated in vivo platform approach to immunotherapy holds great potential to transform the current standard of cancer care by generating safe, broadly accessible immunotherapies that build off of the learnings of existing cell and gene therapy technologies," said David Fontana, Ph.D., Chief Business and Strategy Officer of Umoja Biopharma. "I'm excited to join this forward-thinking team and help Umoja deliver on the promise of our unique technologies to bring effective cancer treatments to patients in need."
About Umoja Biopharma
Umoja Biopharma, Inc. is a pre-clinical stage company headquartered in Seattle, WA. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja is advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Umoja's novel approach is powered by integrated cellular immunotherapy technologies comprising VivoVec in vivo delivery platform, the RACR in vivo cell expansion platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms create and harness a powerful immune response in the body to directly, safely and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit http://umoja-biopharma.com/.
Source: Umoja Biopharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.